29 results
Rheumatoid Arthritis - ACR 2021 Guidelines
 - Low Disease Activity
 - Moderate to High Disease Activity
Arthritis - ACR 2021 Guidelines ... Tapering DMARDs - Treatment ... Rheumatoid #Arthritis #ACR2021 ... #Guidelines #management ... #treatment #rheumatology
Vasculitis Management - ACR/VF 2021 Guidelines for Treatment & Management
 • Giant Cell Arteritis (GCA)
 •
- ACR/VF 2021 Guidelines ... for Treatment & ... #Treatment #ACR2021 ... #Guidelines #algorithm ... #rheumatology
Polyarteritis Nodosa (PAN) - Vasculitis Management Algorithm - ACR/VF 2021 Guidelines
 • Severe Disease → Remission
) - Vasculitis Management ... - ACR/VF 2021 Guidelines ... #Treatment #ACR2021 ... #Guidelines #algorithm ... #rheumatology
Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) - ANCA Vasculitis Management Algorithm - ACR/VF 2021
ANCA Vasculitis Management ... - ACR/VF 2021 Guidelines ... #Treatment #ACR2021 ... #Guidelines #algorithm ... #rheumatology
Systemic Lupus Erythematosus (SLE) - Diagnosis and Management Summary
 • Epidemiology: 10-180/100,000, Typically Age 20-40, F:M
(SLE) - Diagnosis ... and Management ... life-threatening • Treatment ... Erythematosus #Diagnosis ... #rheumatology
Eosinophilic Granulomatosis with Polyangiitis (EGPA) - ANCA Vasculitis Management Algorithm - ACR/VF 2021 Guidelines
 • Active
ANCA Vasculitis Management ... - ACR/VF 2021 Guidelines ... #Treatment #ACR2021 ... #Guidelines #algorithm ... #rheumatology
Giant Cell Arteritis (GCA) - Vasculitis Management Algorithm - ACR/VF 2021 Guidelines
 • Visual Symptoms/Loss or
) - Vasculitis Management ... - ACR/VF 2021 Guidelines ... #Treatment #ACR2021 ... #Guidelines #algorithm ... #rheumatology
CNS Manifestations of Systemic Lupus Erythematosus (SLE)

Clinical Manifestations: Demyelinating Syndrome, Headache, Movement disorders, Seizure disorders, Aseptic
Erythematosus (SLE ... permeability Diagnosis ... Erythematosus #SLE ... CNS #neurology #rheumatology ... #management #treatment
Systemic Lupus Erythematosus - Summary
Antinuclear (ANA) - 95% - Initial screening test
Anti-dsDNA - 50%
 • Associated
Systemic Lupus Erythematosus ... severe disease Treatment ... #Summary #diagnosis ... #rheumatology # ... management
Hydroxychloroquine Serum Measurement in SLE
 • Terminal elimination half-life = 40 days ([HCQI reflects long-term intake)
Measurement in SLE ... 200ng/mL Best indications ... #rheumatology # ... pharmacology #levels #lupus ... #management